A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06821497 USING A 14C-MICROTRACER APPROACH
Latest Information Update: 23 Dec 2024
At a glance
- Drugs Mevrometostat (Primary) ; Mevrometostat (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 18 Dec 2024 Status changed from active, no longer recruiting to completed.
- 13 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2024 Planned End Date changed from 15 Nov 2024 to 13 Nov 2024.